Enamine and BioSolveIT Launch the World's Largest Searchable Chemical Space for Novel Compound Sourcing
Enamine Ltd., a leading chemical research organization and producer of the world’s largest collections of novel building blocks (150,000) and screening compound libraries (2,400,000), and BioSolveIT GmbH, premium provider of medicinal chemistry software, announced the launch of the ‘REAL Space Navigator’. Jointly developed, the new software tool capitalizes on Enamine’s REAL (readily accessible) virtual compound concept and provides efficient ‘search & find’ access to more than 640 million pharma-oriented molecules, to date the world's largest chemical space of commercially accessible compounds.
Searching databases of commercially available compounds is a standard approach to advance hit compounds. However, the global stock of screening compounds has already been largely explored, making the identification of new and promising lead molecules difficult and the need for fast access to novel compounds increasingly necessary.
Enamine can quickly and efficiently assemble new compounds through appropriate single step combinations of the 150,000 building blocks available in its stock. By selecting the most characterized of these and proving their utility in parallel synthesis using 106 reaction protocols developed at Enamine, the Company confidently ensures a minimum synthesis rate of 80% and delivery time of 3-4 weeks. BioSolveIT’s unique software capabilities have allowed for the searchability of a huge virtual chemical space that would be a challenge to navigate using traditional search technologies. REAL Space Navigator can be easily deployed on a standard computer, allowing for convenient, ultra-fast similarity searches and scaffold hopping without the need to connect to the internet and potentially disclose confidential queries.
Michael Bossert, Head of Strategic Alliances at Enamine, commented: “The drug discovery industry has an enormous interest in new chemical compounds. Our REAL concept provides an efficient solution for virtual screening initiatives and analog searches to our clients, who appreciate going beyond the availability bias. BioSolveIT’s fantastic team and its exceptional software platforms have already expanded the borders of Enamine’s REAL database. We will continue to evolve this and hope to put billions of our future tangible molecules at researchers’ fingertips.”
Dr. Christian Lemmen, CEO of BioSolveIT, explained: “Our technology is based on extremely fast tree-based algorithms that avoid visiting every virtual molecule while traversing vast chemistry spaces for interesting hits. With Enamine's outstanding experience in chemical syntheses and quality-driven selection of building blocks, that space is not only impressively large but also packed with unique chemical matter. We are proud to be Enamine's partner in this exciting endeavor and thus offer users of the REAL Space Navigator a considerable competitive advantage.”
Algorithm Speeds Up Medical Image Analysis 1000 TimesNews
Medical image registration is a common technique that involves overlaying two images, such as magnetic resonance imaging (MRI) scans, to compare and analyze anatomical differences in great detail. Researchers have described a machine-learning algorithm that can register brain scans and other 3-D images more than 1,000 times more quickly using novel learning techniques.
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.
Towards Personalized Medicine: One Type of Data is Not EnoughNews
To understand the biology of diseased organs researchers use different types of molecular data. One of the biggest computational challenges at the moment is integrating these multiple data types. A new computational method jointly analyses different types of molecular data and disentangles the sources of disease variability to guide personalized treatment.READ MORE